Rigel Announces Conference Call and Webcast to Report Second Quarter 2026 Financial Results

Rigel Pharmaceuticals (Nasdaq: RIGL) will report its second quarter 2026 financial results after market close on Tuesday, August 4, 2026, followed by a live conference call and webcast at 4:30 p.m. ET (1:30 p.m. PT) led by senior management.

Rhea-AI Summary

Rigel Pharmaceuticals (Nasdaq: RIGL) will report its second quarter 2026 financial results after market close on Tuesday, August 4, 2026, followed by a live conference call and webcast at 4:30 p.m. ET (1:30 p.m. PT) led by senior management.

Investors can join by dialing 877-407-3088 (domestic) or 201-389-0927 (international), or via the webcast in the Investor Relations section of www.rigel.com, where a replay will be available for 90 days.

Argus Jul 28 session

+2.97% close to close Open Argus

Details

News Market Reaction – RIGL

In the Jul 28 session, RIGL gained 2.97%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

Rigel’s prior tag-matched notices recorded 2 positive 24-hour reactions, while this release only sch...

Analysis

Rigel’s prior tag-matched notices recorded 2 positive 24-hour reactions, while this release only schedules the second-quarter report. The platform record adds context, but Net Selling insider activity is a sourced risk to monitor.

Key Figures

Reporting period: Second quarter 2026 Results date: August 4, 2026 Conference call time: 4:30 p.m. Eastern Time +1 more

Reporting period

Second quarter 2026

Financial results announcement

Results date

August 4, 2026

After market close

Conference call time

4:30 p.m. Eastern Time

Following the results announcement

Webcast replay

90 days

Available after the call via Rigel’s website

Previous Conferences,earnings date Reports

2 past events · Latest: Apr 28

Same Type 2 events

1. Apr 28

   1Q26 earnings notice

   24h Move

   +0.2%

   Scheduled first-quarter results and a management conference call for May 5

2. Feb 24

   4Q25 earnings notice

   24h Move

   +0.7%

   Scheduled fourth-quarter and full-year results with a business update

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SOUTH SAN FRANCISCO, Calif., July 28, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will report its second quarter 2026 financial results after market close on Tuesday, August 4, 2026. Rigel senior management will follow the announcement with a live conference call and webcast at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss the financial results and give an update on the business.

Participants can access the live conference call by dialing 877-407-3088 (domestic) or 201-389-0927 (international). The conference call and accompanying slides will also be webcast live and will be accessible from the Investor Relations section of the company's website at www.rigel.com. The webcast will be archived and available for replay for 90 days after the call via the Rigel website.

About Rigel
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) is a biotechnology company dedicated to discovering, developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer. Founded in 1996, Rigel is based in South San Francisco, California. For more information on Rigel, the Company's marketed products and pipeline of potential products, visit www.rigel.com.

Contact for Investors & Media:
Investors:
Rigel Pharmaceuticals, Inc.
650.624.1232
ir@rigel.com 

Media:
David Rosen
Argot Partners
Phone: 646.461.6387
Email: david.rosen@argotpartners.com 

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/rigel-announces-conference-call-and-webcast-to-report-second-quarter-2026-financial-results-302835770.html

SOURCE Rigel Pharmaceuticals, Inc.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Rigel (RIGL) report its second quarter 2026 financial results?

Rigel plans to report its second quarter 2026 financial results on Tuesday, August 4, 2026, after market close. According to Rigel, the announcement will be followed by a management-hosted conference call and webcast that same afternoon.

What time is Rigel's (RIGL) Q2 2026 earnings conference call and webcast?

Rigel's Q2 2026 earnings conference call and webcast is scheduled for 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) on August 4, 2026. According to Rigel, senior management will discuss the quarterly results and provide a business update.

How can investors access the Rigel (RIGL) Q2 2026 earnings call by phone?

Investors can access the Rigel Q2 2026 earnings call by dialing 877-407-3088 in the U.S. or 201-389-0927 internationally. According to Rigel, these numbers provide live access to management’s discussion of financial results and business updates.

Where will the Rigel (RIGL) Q2 2026 earnings webcast be available?

The Rigel Q2 2026 earnings webcast will be available in the Investor Relations section of www.rigel.com. According to Rigel, the webcast will include accompanying slides and will be archived for replay for 90 days after the call.

Will a replay of Rigel's (RIGL) Q2 2026 earnings call be available for investors?

Yes, a replay of Rigel's Q2 2026 earnings call will be available for 90 days after the event via the company’s website. According to Rigel, investors can access the archived webcast through the Investor Relations section at www.rigel.com.

What does Rigel Pharmaceuticals (RIGL) do as a biotechnology company?

Rigel focuses on discovering, developing and providing therapies for hematologic disorders and cancer. According to Rigel, the company is based in South San Francisco and markets products while advancing a pipeline of potential treatments for serious blood and oncology conditions.